Insulet (PODD) Cost of Revenue (2010 - 2026)
Insulet's (PODD) quarterly Cost of Revenue came in at $232.7 million in Q1 2026, up 45.53% YoY from $159.9 million in Q1 2025, and up 8.13% on a QoQ basis from $215.2 million in Q4 2025.
Insulet (PODD) Cost of Revenue (2010 - 2026) Analysis & Trends
Insulet (PODD) has 17 years of Cost of Revenue data on file, last reported at $232.7 million in Q1 2026.
- Quarterly Cost of Revenue rose 45.53% year-over-year to $232.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $841.0 million (up 29.21% YoY) and the FY2025 annual result came in at $768.2 million, up 22.74% from the prior year.
- Cost of Revenue advanced to $232.7 million in Q1 2026, from $215.2 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $232.7 million in Q1 2026 to a low of $85.7 million in Q1 2022.
- A 5-year average of $156.7 million and a median of $152.5 million in 2022 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2022 — Cost of Revenue jumped 75.49% — and 2023, when it dropped 8.59%.
- Tracing PODD's Cost of Revenue over 5 years: stood at $152.4 million in 2022, then declined by 2.49% to $148.6 million in 2023, then gained by 12.11% to $166.6 million in 2024, then advanced by 29.17% to $215.2 million in 2025, then rose by 8.13% to $232.7 million in 2026.
- The last three Cost of Revenue figures came in at $232.7 million (Q1 2026), $215.2 million (Q4 2025), and $196.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|